1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1620
  5. Art Unit 1622
  6. Examiner Leeser

Examiner Leeser Erich A

1622-LEESER-ERICH-A

Employment Information

Art Unit:1622 — Drug, bio-affecting and body treating compositions
Group:1620 — Biomedicinal Chemistry
Classes: 514 — Drug, bio-affecting and body treating compositions
544 — Organic compounds -- part of the class 532-570 series
540 — Organic compounds -- part of the class 532-570 series
546 — Organic compounds -- part of the class 532-570 series
549 — Organic compounds -- part of the class 532-570 series
424 — Drug, bio-affecting and body treating compositions
548 — Organic compounds -- part of the class 532-570 series
585 — Chemistry of hydrocarbon compounds
552 — Organic compounds -- part of the class 532-570 series
257 — Active solid-state devices (e.g., transistors, solid-state diodes)
Phone:(571) 272-9932
Email:erich.leeser@uspto.gov
Location:VA 22314
Title:Pat Examnr Biolgy
Service:20 years
Grade:GS-14

Grant Rate and Difficulty Ranking

28
3-Year Grant rate: 87% over 597 cases
Difficulty: Easier
Difficulty Percentile: 28th

With Examiner Leeser, you have a 87% chance of getting an issued patent by 3 years after the first office action. Examiner Leeser is an easier examiner and in the 28th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Leeser, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1622

Examiner Leeser's grant rate is higher than that of Art Unit 1622 and higher than that of the USPTO.

Average Office Actions Per Grant
Examiner Leeser 0.7
Art Unit 1622 1.1

Interview Benefit

Grant Rate without Interview

Examiner Leeser has granted 439 of 513 cases without any applicant-requested interviews for a grant rate of 86%.

Grant Rate with Interview

Examiner Leeser has granted 80 of 84 cases with at least one applicant-requested interview for a grant rate of 95%.

Interview Benefit

With Examiner Leeser, conducting an interview increases your chance of getting a patent granted by 10%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17914469 A Combination Of Flavonoids And Sphingosine 1 Phosphate Lyase Inhibitors For The Treatment Of Lung Inflammation Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
19195185 Spiromacrocyclic Orexin 2 Receptor Agonists Patented View
18549309 Alpha-1062 For Treating Traumatic Brain Injury Patented View
18027049 Fused Tricyclic Derivative And Pharmaceutical Application Thereof Patented View
17938502 Serine Threonine Kinase (Akt) Degradation / Disruption Compounds And Methods Of Use Abandoned View
17907707 Methods Of Treating Coronavirus Disease 2019 Abandoned View
18070993 Therapeutic Compounds Patented View
18435939 Hybrid Cyclic Libraries And Screens Thereof Patented View
18041864 Tetrahydroquinazoline Derivatives As Selective Cytotoxic Agents Patented View
19072501 Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof Patented View
18394447 Compounds, Compositions And Methods Of Treating Or Preventing Acute Lung Injury Patented View
17956435 Anti-Wolbachia Pyrido[2,3-D]pyrimidine Compounds Patented View
18463865 Pyrazolopyrimidine Compounds As Adenosine Receptor Antagonists Patented View
18382210 Substituted Tricyclic Compounds As Fgfr Inhibitors Patented View
18351278 Combination Therapy Comprising An Alk2 Inhibitor And A Jak2 Inhibitor Abandoned View
18395741 Method Of Inhibiting Kinase By Mesylate Salts Of Triazolopyrazine Derivatives Patented View
17779472 Nuclear Factor Kappa B Pathway Inhibition To Arrest Calcific Aortic Stenosis Abandoned View
16485049 2-Heteroaryl-3-Oxo-2,3-Dihydropyridazine-4-Carboxamides For The Treatment Of Cancer Patented View
18430528 Tertiary Alcohols As Pi3k-Y Inhibitors Patented View
18407744 Method Of Using Mek Inhibitor To Prevent Radiation Induced Fibrosis Abandoned View
18392493 Luteinizing Hormone-Releasing Hormone Receptor (Lhrh-R) Conjugates And Uses Thereof Patented View
17944151 Quinazoline Compounds, Preparation Method, Use, And Pharmaceutical Composition Thereof Patented View
17944149 Quinazoline Compounds, Preparation Method, Use, And Pharmaceutical Composition Thereof Patented View
18508257 Triazolopyrimidine Compounds And Their Use In Treating Cancer Patented View
18085018 Lanthionine Synthetase C-Like 2-Based Therapeutics Patented View
18459675 Irak4 Degraders And Uses Thereof Patented View
18233226 5-(2,5-Difluorophenyl)pyrrolidin-1-Yl)-3-(1h-Pyrazol-1-Yl)pyrazolo [1,5-A]pyrimidine Derivatives And Related Compounds As Trk Kinase Inhibitors For Treating Cancer Patented View
17634580 Curcumin Complex, Preparation Method Therefor And Detection Method Therefor Patented View
17780908 Sphingosine-1-Phosphate Receptor Agonist, Preparation Method Therefor, And Pharmaceutical Composition Containing Same As Active Ingredient Patented View
17832224 Heteroarylaminopyrimidine Amide Autophagy Inhibitors And Methods Of Use Thereof Patented View
18538067 Jak1 Selective Inhibitors Patented View
17784551 Thienopyrimidine Derivatives As Lpa Receptor 2 Inhibitors Abandoned View
18394122 Pyrazolo-Quinazoline Derivatives, Process For Their Preparation And Their Use As Kinase Inhibitors Abandoned View
18496034 Compounds For Treating Spinal Muscular Atrophy Abandoned View
18334976 Solid State Forms Of Substituted Pyrazolopyrimidines And Uses Thereof Abandoned View
19009637 Trem2 Modulators Patented View
18507616 Mek Inhibitors And Uses Thereof Patented View
17788698 Substituted Hydroxystilbene Compounds And Derivatives Synthesis And Uses Thereof Patented View
18321330 Reduction Of The Incidence Or Recurrence Of Breast Cancer In Postmenopausal Women Treated With Intravaginal Sex Steroid Precursor Abandoned View
18107774 Pharmaceutical Composition Containing Palbociclib And Letrozole Abandoned View
17617956 Method For Preparing Cholesterol, Derivative Thereof, And Analog Thereof Patented View
18526408 Spiropiperidine Derivatives Patented View
18237152 Compounds And Methods For Treatment Of Viral Infections Patented View
17910331 Use Of Pyrrolopyrimidine Compound For Treating Hemophagocytic Syndrome Patented View
17914414 N-Cyanopyrrolidines With Activity As Usp30 Inhibitors Abandoned View
18320111 Inhibitors Of The Menin-Mll Interaction Abandoned View
18091790 Pyrimidine Compound Abandoned View
18225966 Therapeutic Compounds Patented View
18526380 Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates Patented View
18196357 Spiro Aromatic Ring Compound And Use Thereof Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.